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Abstract
Background: Increased levels of circulating fatty acids caused by insulin resistance and increased
adipocyte lipolysis can accumulate within the liver resulting in steatosis. This steatosis sensitizes the
liver to inflammation and further injury which can lead to liver dysfunction. We performed
microarray analysis on normal mouse liver tissue at different ages and type 2 diabetic liver exhibiting
steatosis to identify differentially expressed genes involved in lipid accumulation and liver
dysfunction.
Results: Microarray analysis identified CIDE-A as the most differentially expressed gene as a
function of age. Mice fed a high fat diet developed hyperinsulinemia, hyperglycemia and liver
steatosis, all features of the human metabolic syndrome. Increased CIDE-A expression was
observed in type 2 diabetic liver and the elevated CIDE-A expression could be reversed by weight
loss and normalization of plasma insulin. Also, CIDE-A expression was found to be correlated with
hepatic lipid accumulation.
Conclusion: The corresponding increase in CIDE-A expression with hyperinsulinemia and liver
steatosis suggests a novel pathway for lipid accumulation in the liver.
Background
Non-alcoholic fatty liver disease (NAFLD) is one of the
most common causes of liver disease and is estimated to
affect 10 to 24% of the general population in western
nations [1]. While NAFLD is a serious problem, effective
treatments are still lacking. NAFLD is characterized by a
wide spectrum of liver damage ranging from simple stea-
tosis to steatohepatitis (NASH) to advanced fibrosis and
cirrhosis [2]. Hepatic steatosis is caused by lipid accumu-
lation within hepatocytes and is a relatively benign condi-
tion. However, steatosis combined with necro-
inflammatory activity may progress to end-stage liver dis-
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ease [3-7]. The higher prevalence of NAFLD in persons
with obesity, hyperinsulinemia or type 2 diabetes suggests
that elevated circulating fatty acid concentrations caused
by insulin resistance and increased adipocyte lipolysis
plays a pivotal role in the development of this syndrome
[1,8].
CIDE-A (cell-death-inducing DFF45-like effector-A) is a
member of a family of proapoptotic proteins that includes
CIDE-B and CIDE-3/FSP27 [9-11]. Whereas CIDE-A is
capable of inducing apoptosis, CIDE-A also plays a role in
regulating energy balance and lipid metabolism [12].
CIDE-A gene disrupted mice (CIDE-A -/-) have a lean phe-
notype and are resistant to diet-induced obesity and pos-
sibly diabetes [12]. CIDE-A also interacts and inhibits
uncoupling protein-1 (UCP-1) resulting in greater energy
expenditure in brown adipose tissue (BAT) and less lipid
accumulation in white adipose tissue (WAT) [13]. Like-
wise, the lack of CIDE-A in gene disrupted mice results in
increased thermogenesis, energy expenditure and lipolysis
[14].
In humans, CIDE-A expression in adipose tissue is nega-
tively correlated with fat mass [15,16]. That is, CIDE-A has
been shown to be decreased 2-fold in subcutaneous WAT
of obese humans yet highly upregulated in obese individ-
uals undergoing weight reduction [16]. In addition, a sin-
gle nucleotide polymorphism (V115F) has been shown to
be associated with obesity in a Swedish population [17].
Previous reports have indicated that CIDE-A is not
expressed in normal adult human or mouse liver tissue
[9,12]. However, CIDE-A has been detected in the liver of
mice treated with the hypolipidemic compound and
potent peroxisome proliferator, WY-14,643 [18,19]. Due
to the recent reports describing a role for CIDE-A in the
regulation of lipid metabolism, we examined CIDE-A
expression in liver of normal mice at various ages and in a
mouse model of diet-induced type 2 diabetes and liver
steatosis.
Results
CIDE-A is expressed in the liver of old mice
Microarray analysis was used to identify differences in
liver gene expression in aging mice. The mice were sacri-
ficed at ages ranging from 56 to 725 days. A total of 190
genes were differentially expressed by at least a 2-fold
magnitude between 2 time points. Analysis identified
CIDE-A as the most differentially expressed gene in liver
during this age span (Fig. 1). CIDE-A expression was not
detected at 56 days of age (expression level less than 0.2).
The expression of CIDE-A was barely detectable at 118
and 207 days of age (0.59, 0.13 and 0.13, 0.34, respec-
tively). However, CIDE-A is readily detected at 403 days of
age (5.5, 1.5) and the level of expression continues to
increase at 558 days of age (7.83, 7.59). Taken together,
the level of CIDE-A expression in liver increases at least
38-fold as the mouse progresses from 56 days of age to
maximal expression at 558 days of age.
Liver steatosis is observed in CIDE-A expressing older mice
H&E stained liver sections prepared from mice of various
ages were examined to determine if increased CIDE-A
expression correlated with any noticeable histological
changes in the livers of these mice (Fig. 2). Although only
a single liver sample was analyzed at each time point,
there was a tendency for the percent white space to
increase with age (2 months = 7.98% vs 18 months =
9.15% vs 24 months = 9.98%). (While this observation is
by no means conclusive, it does provide a basis for addi-
tional investigation.)
CIDE-A expression is increased in type 2 diabetic mice
Due to the correlation of increased CIDE-A expression
with increasing age, we investigated whether CIDE-A
expression would also be increased in a model of diet-
induced obesity and type 2 diabetes [20-22]. DNA micro-
array analysis of RNA isolated from liver tissue of control
and type 2 diabetic mice identified 466 genes whose
expression is altered by at least 2-fold between normal
and type 2 diabetic tissues. The level of CIDE-A expression
in these tissues is shown in Figure 3.
In agreement with the above data, CIDE-A expression (<
0.2 background) was not detected in the livers of mice fed
the normal diet at 35, 49 or 77 days of age (2, 4, or 8
weeks on diet). The expression of CIDE-A was barely
detectable at 133 days of age (16 weeks on diet: 0.31,
0.19) and begun to rise at 203 days of age (26 weeks on
diet: 1.28, 0.87). In contrast, the expression of CIDE-A in
the liver of type 2 diabetic mice fed a high-fat diet was
detected at 77 days of age (8 weeks on diet: 0.25, 0.16)
and continued to rise rapidly at 133 and 203 days of age
(16 and 26 weeks on diet: 1.73, 0.96 and 3.34, 6.77,
respectively). This represents a 5-fold increase in CIDE-A
gene expression. We also performed Northern and immu-
noblot analyses of liver tissue to confirm the CIDE-A
expression patterns (Fig. 4). The 1.3 kb CIDE-A mRNA
was not detected in control liver samples whose CIDE-A
microarray expression levels were 0.87 and 2.78. How-
ever, CIDE-A mRNA was faintly visible in the 26 week dia-
betic liver and was much more prevalent in the 42 week
diabetic liver expressing high levels of CIDE-A. The CIDE-
A expression levels as determined by microarray analysis
were 6.77 and 24.52. CIDE-A mRNA was also detected in
control and diabetic heart tissue as previously reported
(9). Immunoblot analysis only detected CIDE-A in liver
expressing the highest level of mRNA (42 week diabetic
liver).Comparative Hepatology 2007, 6:4 http://www.comparative-hepatology.com/content/6/1/4
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Liver steatosis induced by high-fat diet
In addition to causing obesity and type 2 diabetes, the
feeding of a high fat diet such as that used in these exper-
iments to C57BL/6J mice, also causes lipid accumulation
within the liver (steatosis) [23-28]. We performed histo-
logical examinations on H&E stained liver sections pre-
pared from control and type 2 diabetic mice after 2, 16
and 26 weeks of feeding to assess the degree of liver stea-
tosis (Figs. 5, 6).
Hepatocytes from control and diabetic mice contained
approximately the same level of lipid at 2 (individual val-
ues – control: 10.2%, 7.7%; diabetic: 9.7%, 9.2%) and 4
weeks (individual values – control: 9.3%, 8.1%; diabetic:
13.6%, 8.8%) on the respective diets. However, by 8
weeks, hepatocytes from diabetic mice liver tissue isolated
from high fat-fed mice contain more lipid than their con-
trol counterparts (individual values – control: 10.3%,
8.9%; diabetic: 18.0%, 13.0%). Severe liver steatosis was
Increased liver steatosis in older mice Figure 2
Increased liver steatosis in older mice. H&E stained liver sections isolated from mice fed standard chow at 56 (A), 558 (B) 
and 725 (C) days of age shows the accumulation of lipid in liver hepatocytes of older mice.
56 Days                                                 558 Days 725  Days
50 μm 50 μm 50 μm A BC
CIDE-A is expressed in liver of aging mice Figure 1
CIDE-A is expressed in liver of aging mice. Amersham CodeLink Expression Bioarrays™ were performed on bioti-
nylated cRNA generated from poly(A) mRNA isolated from the liver of mice ranging from 56 to 725 days of age. Expression 
levels relate to fluorescence detected from processed DNA microarrays. The CIDE-A expression value in each individual liver 
is shown.
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observed in mice fed the high-fat diet for 16 weeks and
was even more pronounced after 26 weeks of high-fat
feeding. The percent white space in these livers was 33.6%
and 27.0% at 16 weeks and 45.0% and 61.3% at 26
weeks. In comparison, the percent white space in liver tis-
sue of mice fed the normal diet for 16 weeks was 8.6% and
10.6% and is 12.5% and 11.8% for those at 26 weeks. The
changes in percent white space were positively correlated
with CIDE-A expression levels as determined by microar-
ray analysis (r = 0.94; P < 0.001).
Effect of diet-reversal on CIDE-A expression
Previous reports have indicated that the type 2 diabetic
condition generated in high fat-fed mice can be reversed
by returning type 2 diabetic mice to standard chow [29].
We therefore performed a similar diet-reversal study to
determine its effects on CIDE-A expression in the liver.
Animal weights, plasma insulin and fasting blood glucose
levels at time of sacrifice are shown in Table I. Liver tissue
was isolated from control, high fat-fed and diet reversed
mice and CIDE-A expression levels were determined by
real-time PCR (Fig. 7). In agreement with the above data,
mice fed a high fat diet for the entire period (HF-HF)
exhibited a statistically significant 3.8-fold increase in
CIDE-A expression (0.21, 0.45, 0.24 and 0.30 vs 0.11,
0.18, 0.02 and 0.01 for HF and control, respectively).
These mice also exhibited elevated weight and insulin lev-
els relative to control mice. Mice switched to standard
CIDE-A expression is increased in the type 2 diabetic liver Figure 3
CIDE-A expression is increased in the type 2 diabetic liver. Amersham CodeLink Expression Bioarrays™ were per-
formed on biotinylated cRNA generated from poly(A) mRNA isolated from the liver of mice ranging from 35 to 203 days of 
age (2, 4, 8, 16 and 26 weeks on diet). The CIDE-A expression value in each individual liver is shown. Black boxes: Type 2 dia-
betic mice fed the high fat diet. Open triangles: control mice fed standard chow. Expression levels relate to fluorescence 
detected from processed DNA microarrays.
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Table 1: Effect of diet reversal on weight, insulin and glucose levels of type 2 diabetic mice.
Diet Weight (g) Plasma Insulin (ng/ml) Fasting Glucose (mg/dl)
SC-SC 35.1 (3.5)a 326 (190)a 150 (13.8)a
HF-HF 56.5 (5.3)b 1981 (1170)b 153 (17.9)a
HF-SC 37.1 (1.9)a 247 (104)a 114 (11.4)b
Values are: mean (SD). N = 4 (for each group). Means in a column without a common letter differ significantly, P < 0.05. SC denotes mice fed 
standard chow; HF denotes mice fed the high fat diet; HF-SC denotes diet-reversed mice that were first fed the high fat diet and switched to 
standard chow.Comparative Hepatology 2007, 6:4 http://www.comparative-hepatology.com/content/6/1/4
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chow from a high fat diet (HF-SC) demonstrated normal-
ized weight and insulin levels and a significantly lower
blood glucose level. CIDE-A expression in these mice was
also drastically reduced, falling to a level only 44% that
seen in the control mice, although this decrease was not
statistically significant (0.03, 0.09, 0.01 and 0.01 vs. 0.11,
0.18, 0.02 and 0.01 for diet-reversed and control, respec-
tively). CIDE-A expression levels were positively corre-
lated with both weight (r  = 0.8; P  < 0.005) and with
insulin levels (r = 0.8; P < 0.005) but was not correlated
with glucose levels. (These data indicate that CIDE-A
expression was more closely correlated to plasma insulin
levels and weight than to fasting blood glucose and sug-
gests that increased CIDE-A expression precedes elevated
blood glucose during the onset of obesity-induced type 2
diabetes.)
Discussion
While liver steatosis and its associated diseases represent
an ever increasing health problem, the key pathways and
metabolic processes involved in the development of this
disease are not fully understood and effective therapies are
CIDE-A Northern and Immunoblot analyses Figure 4
CIDE-A Northern and Immunoblot analyses. A) Northern analysis of RNA extracted from normal (C) and type 2 dia-
betic (D) liver and heart tissue. Total RNA (10 μg) from the appropriate tissues was resolved by denaturing agarose gel elec-
trophoresis, transferred to positively charged nylon membrane, hybridized with the [α-32P]dCTP-labeled mouse CIDE-A 
cDNA and exposed to Bio-Max MR film. Ethidium bromide stain of RNA (10 μg/lane) prior to transfer to nylon membrane. 
The values represent the level of CIDE-A gene expression for the individual tissue as determined by DNA microarray analysis 
(ND: not determined). The approximated size (1.3 kb) of the CIDE-A mRNA is noted on the right. B) Immunoblot demon-
strating increased CIDE-A protein levels in type 2 diabetic mouse liver. Sixty μg of liver and heart extract was electrophoresed 
on a 12.5% SDS-polyacrylamide gel and the resolved proteins transferred to a nitrocellulose membrane. The membrane was 
immunoblotted using a rabbit anti-mouse CIDE-A polyclonal antibody and a goat anti-rabbit IgG polyclonal antibody conjugated 
to horseradish peroxidase. Arrow indicates mouse CIDE-A. The values represent the level of CIDE-A gene expression for the 
individual tissue as determined by DNA microarray analysis (ND: not determined).
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lacking. In this report, we describe a new pathway that
may be involved in liver steatosis. We demonstrate that
CIDE-A is expressed in liver of old mice. In fact, DNA
microarray analysis indicates that CIDE-A is the most dif-
ferentially expressed liver gene between young and older
mice (38-fold increase). The increased expression of
CIDE-A may not be due solely to increased age per se, but
more likely a consequence of increased insulin resistance
in the mice at older ages [30]. Insulin resistance is a com-
mon occurrence in aging individuals and is believed to be
caused by increased adiposity rather than the aging proc-
ess [31-36]. CIDE-A expression is also increased in a
model of diet-induced type 2 diabetes. Increased CIDE-A
expression was confirmed by Northern and immunoblot
analyses. Elevated CIDE-A expression can be reversed by
weight loss and normalization of plasma insulin. Also,
CIDE-A expression was found to be correlated with
hepatic lipid accumulation.
Previous reports have indicated that human and mouse
CIDE-A are expressed in several tissues such as BAT, WAT,
heart, lymph node, thymus, skeletal muscle and is local-
ized to the mitochondria [9,15]. In another study, CIDE-
A-deficient mice were found to have a lean phenotype and
are resistant to obesity [12]. We believe that CIDE-A
expression was not previously detected in liver due to the
use of tissue from an inappropriate age or condition. Our
data would suggest that human liver from older, insulin
resistant or diabetic individuals may express this protein.
This study has identified CIDE-A as another potential
mediator of lipid accumulation in liver hepatocytes. A
recent study has proposed a human-specific role for CIDE-
A in lipolysis and metabolic complications [15]. The pre-
vious study demonstrated that CIDE-A is expressed in
human WAT with its expression decreased twofold in
obese humans and normalized after weight loss. Reduced
CIDE-A expression results in increased TNF-α secretion
and basal lipolysis in subcutaneous WAT [15]. Increased
TNF-α secretion also further decreases CIDE-A expression
via TNF-α signaling through c-Jun NH2-terminal kinase
(JNK) [15]. With this data, a model has emerged describ-
ing the role of CIDE-A in elevation of circulating FFA. Spe-
cifically, a decrease in CIDE-A expression results in
increased TNF-α secretion resulting in increased lipolysis.
The increased basal WAT lipolysis induced by low CIDE-
A levels and elevated TNF-α secretion results in elevated
levels of circulating fatty acid which can then be redirected
to other tissues such as the liver. According to the model,
increased CIDE-A expression and subsequent decreased
TNF-α secretion would lead to decreased lipolysis and the
accumulation of lipid within the tissue. Thus, increased
Steatosis in liver of high-fat diet fed mice Figure 5
Steatosis in liver of high-fat diet fed mice. Mice were weaned directly onto either standard chow or a high-fat diet and 
maintained on the respective diets for up to 26 weeks. The mice were sacrificed and liver tissue isolated. Histology was per-
formed on H&E stained liver tissue as described.
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CIDE-A expression in hepatocytes as a result of insulin
resistance and type 2 diabetes may promote the uptake of
increased circulating fatty acids released from WAT and
lead to steatosis.
CIDE-A has been postulated to play a role in apoptosis
suggesting the intriguing possibility that CIDE-A may play
a role in apoptosis associated with liver steatosis and
NAFLD. Disease progression from benign steatosis
involves injury and an inflammatory response [4]. While
the cause of the injury is not understood, it is clear that
cellular apoptosis represents one of the first responses to
injury and is a prominent feature of NAFLD as well as
other diseases such as viral hepatitis, alcohol-induced
liver disease, cholestatic liver diseases and ischemia/per-
fusion injury [3-7,37,38]. We did not, however detect
increased apoptosis in CIDE-A expressing livers samples
by TUNEL analysis and therefore believe that CIDE-A
main function in the liver involves lipid metabolism.
Conclusion
CIDE-A is expressed in normal adult mouse liver at older
ages and is expressed in the liver of hyperinsulinemic and
type 2 diabetic mice. CIDE-A expression positively corre-
lates with liver steatosis in a mouse model of obesity-
induced type 2 diabetes. These observations suggest a
novel role for CIDE-A in the lipid accumulation character-
istic of liver steatosis.
Future experiments that further delineate CIDE-A expres-
sion and effects will shed light on its function in the liver.
Definitive experiments include placing the CIDE-A null
mice, described by Zhou et al. [12], on the described high
fat diet and assessing the effect of the lack of CIDE-A on
liver steatosis and type 2 diabetes. The complementary
experiment of generating transgenic mice expressing
CIDE-A in the liver and assessing its effect under the same
conditions may provide clues to CIDE-A function. Regard-
less, these data provide compelling evidence that CIDE-A
exists in the liver and further suggests that CIDE-A expres-
sion levels are radically altered in mice as a function of age
and/or metabolic state.
Materials and methods
Animal models used to identify differentially expressed 
liver genes
All experimental protocols were approved by the Ohio
University Animal Care and Utilization Committee.
For the analysis of gene expression during the aging proc-
ess, twelve male C57Bl/6J mice were fed standard chow
(PMI Nutrition International Inc., Brentwood, MO, Pro-
Quantification of percent liver white space Figure 6
Quantification of percent liver white space. Image analysis was made as described in methods. The CIDE-A expression 
value in each individual liver is shown. Black boxes: Type 2 diabetic mice fed the high fat diet. Open triangles: control mice fed 
standard chow. Expression levels relate to fluorescence detected from processed DNA microarrays.
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lab RMH3000) immediately following weaning. Mice
were sacrificed at 35, 49, 56, 77, 133, 207, 403, 558 and
725 days of age. A portion of the left lateral lobe of the
liver was placed in 4% paraformaldehyde and the remain-
ing tissue was frozen in liquid nitrogen until processed for
RNA isolation. For the analysis of normal versus diabetic
liver gene expression, we utilized a mouse model of obes-
ity-induced type 2 diabetes first described by Surwit [20]
and replicated successfully in our laboratory and others
[21,22]. Mice were weaned at 3 weeks onto either stand-
ard chow or a high-fat diet (BioServe, Frenchtown, NJ.
#F1850) for up to 26 weeks. Representative mice were sac-
rificed after 2, 4, 8, 16 and 26 weeks on the diet (35, 49,
77, 133 and 203 days of age) and liver tissue was isolated.
Mice fed standard chow served as control animals. Type 2
diabetic mice were characterized as having > 200 mg/dl
fasting blood glucose and at least a 2-fold increase in fast-
ing plasma insulin compared to control mice.
For diet-reversal analysis, C57Bl/6J mice were weaned
onto a standard chow (SC) diet and maintained for 47
weeks. A second set of mice were weaned onto a high-fat
diet (HF) diet for 33 weeks. One half of the high-fat fed
mice were maintained on the high-fat diet while the other
half was switched to standard chow for a period of 14
weeks. Food and water were supplied ad libitum through-
out the course of the studies. Following the 47 week feed-
ing period, the animals were sacrificed and liver tissue
isolated as described above.
Glucose and insulin levels
Blood-glucose levels were measured from blood taken
from the tip of the tail of fasted (8 hr) mice using a One
Touch glucometer (Life scan). All measurements occurred
between 2:00 and 5:00 pm. Insulin concentrations were
determined using the Ultrasensitive Rat Insulin ELISA kit
(ALPCO, Windham, NH) as instructed by the manufac-
turer. Values were adjusted by a factor of 1.23 as deter-
Effect of diet-reversal on CIDE-A expression Figure 7
Effect of diet-reversal on CIDE-A expression. Mice were weaned onto the indicated diet for 33 weeks. The mice were 
then switched to the indicated diets for an additional 14 weeks. RNA was isolated from frozen liver as described. Real Time 
RT-PCR was performed on the cDNA transcripts using CIDE-A forward and reverse primers. Housekeeping genes, ACTG 
(actin gamma cytoplasmic) and GADPH (glyceraldehyde-III phosphate dehydrogenase), were utilized for normalization as 
described. Relative expression levels were calculated using normalization factors derived from geNorm analysis of ACTG and 
GADPH using the delta-delta CT method. CIDE-A expression levels in control mice fed standard chow for the entire feeding 
period (SC-SC) were given a value of 1.0. Changes in CIDE-A expression due to diet were expressed relative to the control 
mice. N = 4 (for each group). SC, standard chow; HF, high-fat diet.
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mined by the manufacturer to correct for the species
difference in cross-reactivity with the antibody.
Microarray analysis
Total RNA was isolated from whole liver using the RNA
STAT-60 Total RNA/mRNA Isolation Reagent according to
the manufacturer's instructions (Tel-Test, Friendswood,
TX). Biotinylated cRNA hybridization target was prepared
by a linear amplification method as described in the man-
ufacturer's instructions for CodeLink Expression Bioar-
rays™ (Amersham Biosciences). The oligonucleotide
probes were provided by the Codelink Uniset Mouse I
Bioarray (Amersham, product code 300013). CodeLink
Expression Bioarrays™ contain 10,000 oligonucleotide
probes, each specific to a well-characterized mouse gene.
Using the cRNA target, the hybridization reaction mixture
containing the biotinylated target cRNA was loaded into
array chambers for bioarray processing as described in the
manufacturer's instructions for CodeLink Gene Expres-
sion BioarraysTM (Amersham Biosciences). Each sample
was hybridized at 37°C to an individual microarray.
Hybridization was detected with an avidinated fluores-
cent reagent, Streptavidin-Alexa Fluor ® 647 (Amersham).
Processed arrays were scanned using a GenePix 4000B
Microarray Scanner (Axon Instruments, Inc.). Array
images were acquired using the Amersham CodeLink
Analysis Software (Release 2.2). A significant difference in
expression between samples was defined as a minimum
of 2-fold change in expression values.
Real-time RT-PCR
RNA was isolated from frozen liver as described above.
cDNA transcripts were created using iScript cDNA Synthe-
sis Kit (Cat# 170-8891, Bio-Rad Laboratories, Hercules,
CA). Real Time RT-PCR was performed on the Bio-Rad
iCycler iQ Real Time PCR Detection System (Cat# 170-
8740, Bio-Rad Laboratories) using IQ SYBR Green Super-
mix (Cat# 170-8882). CIDE-A primers (Forward Primer:
5'CTCGGCTGTCTCAATGTCAA3'; Reverse Primer:
5'CCGCATAGACCAGGAACTGT3' were designed using
Primer3 online software [39]. Housekeeping genes, ACTG
(actin gamma cytoplasmic) and GADPH (glyceraldehyde-
III phosphate dehydrogenase) were utilized for normali-
zation as described by Vandesompele et al. [40,39]. Rela-
tive expression levels were then calculated using
normalization factors derived from geNorm analysis of
ACTG and GADPH using the delta-delta CT method [40].
Liver histology and image analysis
Liver tissues fixed in 4% paraformaldehyde were embed-
ded in Tissue Path (Fisher Scientific, Pittsburgh, PA).
Embedded tissue was sectioned for seven microns thick-
ness, stained with H&E and evaluated by an automated
light microscopy system, consisting of a 20 × lens with 0.5
NA, scanning stage, 3-color CCD camera and image anal-
ysis software and database (Icoria Inc, Research Triangle
Park, NC). Images were taken at 0.64 micron resolution
and were automatically assembled into montages. From
300 to 500 single images were captured to represent a sin-
gle tissue section. These montages were then used for sub-
sequent automated analysis of both gross anatomical
features and fine tissue structures using automated pathol-
ogy software [41,42]. Tissue metrics included counts, area,
density and size of hepatocyte nuclei, non-hepatocyte
nuclei, percent intracellular and extracellular white space.
The feature intracellular white space calculated the
amount of white space within hepatic boundaries, the
appearance of which is consistent with lipid accumulation
in this study. Application of these methods resulted in dis-
tinct tissue profiles for all animals.
Northern analysis
Total RNA (10 μg) from appropriate tissues was resolved
by denaturing agarose gel electrophoresis, transferred to
nylon membrane, hybridized with the [α-32P]dCTP-
labeled mouse CIDE-A cDNA (Random Primed DNA
Labeling Kit, Roche, Indianapolis, IN) and exposed to
Bio-Max MR film (Eastman Kodak Co., Rochester, NY).
Immunoblot analysis
Liver and heart tissue (100 mg) was homogenized in 0.5
ml phosphate buffered saline containing 7.5 μl protease
inhibitor cocktail (Sigma #P8340, St. Louis, MO). The
samples were centrifuged for 5 min at 10,000 g. The super-
natant was collected and protein concentration deter-
mined (Bio-Rad Laboratories #500-0006, Hercules, CA).
Sixty μg of each extract was electrophoresed on a 12.5%
SDS-polyacrylamide gel as described [43]. Resolved pro-
teins were transferred to a nitrocellulose membrane and
immunoblotted using a rabbit anti-mouse CIDE-A poly-
clonal antibody (QED Bioscience Inc., San Diego, CA) as
previously described [43].
Statistical analysis
Data are reported as dot plots or as mean (SD). Differ-
ences between two groups were assessed using the
unpaired two-tailed Student's t  test. For comparisons
between multiple groups, ANOVA followed by Tukey's
multiple-comparisons test was used. Analysis of correla-
tions was done with Pearson correlation coefficients. Sta-
tistical significance was indicated by P  value less than
0.05. SigmaStat statistics software (version 12.0; SPSS)
was used for all calculations.
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